GlassScriptPhysician profile
Mohammed N Ahmed
NPI 1053460923
$9,023.21
in general payments reported to CMS, 2019-2025
26 companies · $1,456 in 2025
The $1,456 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,267 · 2020: $233 · 2021: $582 · 2022: $630 · 2023: $1,972 · 2024: $883 · 2025: $1,456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,512 · Travel and Lodging: $1,800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,511.76 |
| Travel and Lodging | $1,799.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,799.52 | 2023-2025 | Abre, Evera Mri Xt Dr Surescan |
| Abbott Laboratories | $1,385.18 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $906.04 | 2019-2025 | Lifevest |
| Boston Scientific Corporation | $790.73 | 2019-2023 | |
| Abiomed | $735.62 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $637.90 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $603.22 | 2022-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $418.35 | 2021-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $350.04 | 2019-2024 | Andexxa, Farxiga, Wainua |
| Janssen Pharmaceuticals, INC | $256.83 | 2019-2022 | |
| Kestra Medical Technology Services, INC. | $182.34 | 2023-2025 | Assure Wcd |
| Impulse Dynamics (USA) INC. | $152.19 | 2024-2025 | Optimizer |
| Medtronic Vascular, INC. | $143.68 | 2019-2020 | |
| Novo Nordisk INC | $139.52 | 2019-2023 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.90 | 2019-2023 | Jardiance |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $92.59 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $55.55 | 2019 | |
| Lundbeck LLC | $48.52 | 2019 | |
| Scpharmaceuticals INC. | $36.80 | 2024 | |
| Amgen INC. | $30.81 | 2019-2022 | |
| Daiichi Sankyo INC. | $28.11 | 2025 | Injectafer |
| Sanofi-Aventis U.S. LLC | $24.84 | 2023 | |
| Fisher & Paykel Healthcare INC | $22.03 | 2023 | Fisher & Paykel Healthcare |
| Vifor Pharma, INC. | $21.80 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $20.10 | 2024 | Arcalyst |
| Irhythm Technologies, INC. | $15.00 | 2024 | Zio Monitor, Zio Xt Patch |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.